HRP20130935T1 - Bicikliäśki derivat aminokiseline - Google Patents
Bicikliäśki derivat aminokiseline Download PDFInfo
- Publication number
- HRP20130935T1 HRP20130935T1 HRP20130935AT HRP20130935T HRP20130935T1 HR P20130935 T1 HRP20130935 T1 HR P20130935T1 HR P20130935A T HRP20130935A T HR P20130935AT HR P20130935 T HRP20130935 T HR P20130935T HR P20130935 T1 HRP20130935 T1 HR P20130935T1
- Authority
- HR
- Croatia
- Prior art keywords
- pain
- hept
- aminomethyl
- acceptable salt
- acetic acid
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 208000004296 neuralgia Diseases 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 9
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 208000001640 Fibromyalgia Diseases 0.000 claims 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 206010068106 Occipital neuralgia Diseases 0.000 claims 2
- 206010040744 Sinus headache Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- FTBQORVNHOIASH-CKYFFXLPSA-N 2-[(1r,5s,6s)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid Chemical compound C1C(CC)=C[C@H]2[C@](CC(O)=O)(CN)C[C@H]21 FTBQORVNHOIASH-CKYFFXLPSA-N 0.000 claims 1
- XLHFKEUBYVYWDW-TXULWXBWSA-N 2-[(1r,5s,6s)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1C(CC)=C[C@H]2[C@](CC(O)=O)(CN)C[C@H]21 XLHFKEUBYVYWDW-TXULWXBWSA-N 0.000 claims 1
- OKJXJRVWXYRSAN-TXULWXBWSA-N 2-[(1r,5s,6s)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid;benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1C(CC)=C[C@H]2[C@](CC(O)=O)(CN)C[C@H]21 OKJXJRVWXYRSAN-TXULWXBWSA-N 0.000 claims 1
- IAPOKOJFOPJHGH-NQMVMOMDSA-N 2-[(1r,5s,6s)-6-(aminomethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetic acid Chemical compound C1C=C[C@H]2[C@@](CN)(CC(O)=O)C[C@H]21 IAPOKOJFOPJHGH-NQMVMOMDSA-N 0.000 claims 1
- FTBQORVNHOIASH-NHCYSSNCSA-N 2-[(1s,5r,6r)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid Chemical compound C1C(CC)=C[C@@H]2[C@@](CC(O)=O)(CN)C[C@@H]21 FTBQORVNHOIASH-NHCYSSNCSA-N 0.000 claims 1
- IAPOKOJFOPJHGH-NRPADANISA-N 2-[(1s,5r,6r)-6-(aminomethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetic acid Chemical compound C1C=C[C@@H]2[C@](CN)(CC(O)=O)C[C@@H]21 IAPOKOJFOPJHGH-NRPADANISA-N 0.000 claims 1
- ZKXGADLGDBFHMQ-KBMNZXMKSA-N 2-[(1s,5r,6r)-6-(aminomethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetic acid;benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1C=C[C@@H]2[C@](CN)(CC(O)=O)C[C@@H]21 ZKXGADLGDBFHMQ-KBMNZXMKSA-N 0.000 claims 1
- ZLCLUSBQLYEXSG-KBMNZXMKSA-N 2-[(1s,5r,6r)-6-(aminomethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetic acid;hydrochloride Chemical compound Cl.C1C=C[C@@H]2[C@](CN)(CC(O)=O)C[C@@H]21 ZLCLUSBQLYEXSG-KBMNZXMKSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 208000001375 Facial Neuralgia Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010049949 Intercostal neuralgia Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 206010024453 Ligament sprain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000037158 Partial Epilepsies Diseases 0.000 claims 1
- 206010061334 Partial seizures Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010049002 Scar pain Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000026137 Soft tissue injury Diseases 0.000 claims 1
- 208000010040 Sprains and Strains Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 208000012790 cranial neuralgia Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000007186 focal epilepsy Diseases 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
- 210000004086 maxillary sinus Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001107 psychogenic effect Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/613—Unsaturated compounds containing a keto groups being part of a ring polycyclic
- C07C49/617—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system
- C07C49/623—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings
- C07C49/627—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having two rings the condensed ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/32—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Claims (16)
1. Spoj predstavljen općom formulom (I) ili njegova farmakološki prihvatljiva sol:
[image]
gdje
R1, R2, R2’, R4, R5, R6, R7, R8, i R8’ su svaki nezavisno atom vodika; i
R3 je atom vodika, metilna skupina, etilna skupina, propilna skupina, ili butilna skupina.
2. Spoj prema zahtjevu 1 ili njegova farmakološki prihvatljiva sol, gdje R3 je atom vodika ili etilna skupina.
3. Farmakološki prihvatljiva sol spoja prema zahtjevu 1 ili zahtjevu 2, gdje je farmakološki prihvatljiva sol klorovodik, benzensulfonat ili p-toluensulfonat.
4. Spoj prema zahtjevu 1 ili njegova farmakološki prihvatljiva sol, predstavljen općom formulom (Ia) ili njegova farmakološki prihvatljiva sol:
[image]
gdje
R1, R2, R2’, R3, R4, R5, R6, R7, R8, i R8’ su kako je definirano u zahtjevu 1.
5. Spoj prema zahtjevu 1 ili njegova farmakološki prihvatljiva sol, predstavljen općom formulom (Ib) ili njegova farmakološki prihvatljiva sol:
[image]
gdje
R1, R2, R2’, R3, R4, R5, R6, R7, R8, i R8’ su kako je definirano u zahtjevu 1.
6. Spoj prema zahtjevu 1 ili njegova farmakološki prihvatljiva sol, izabrani iz grupe koja obuhvaća sljedeće:
(6)-[(1S,5R,6R)-6-(aminometil)biciklo(3.2.0)hept-3-en-6-il]octena kiselina;
(6)-[(1S,5R,6R)-6-aminometil-3-metilbiciklo[3.2.0]hept-3-en-6-il]octena kiselina;
(6)-[(1S,5R,6R)-6-aminometil-3-etilbiciklo[3.2.0]hept-3-en-6-il]octena kiselina;
(6)-[(1S,5R,6R)-6-aminometil-3-propilbiciklo[3.2.0]hept-3-en-6-il]octena kiselina;
(6)-[(1S,5R,6R)-6-aminometil-3-butilbiciklo[3.2.0]hept-3-en-6-il]octena kiselina;
[(1R,5S,6S)-6-(aminometil)biciklo[3.2.0]hept-3-en-6-il]octena kiselina;
[(1S,5R,6R)-6-(aminometil)biciklo[3.2.0]hept-3-en-6-il]octena kiselina;
[(1S,5R,6R)-6-(aminometil)biciklo[3.2.0]hept-3-en-6-il]octena kiselina klorovodik;
[(1S,5R,6R)-6-(aminometil)biciklo[3.2.0]hept-3-en-6-il]octena kiselina benzensulfonat;
[(1R,5S,6S)-6-aminometil-3-etilbiciklo[3.2.0]hept-3-en-6-il]octena kiselina;
[(1R,5S,6S)-6-aminometil-3-etilbiciklo[3.2.0]hept-3-en-6-il]octena kiselina p-toluensulfonat;
[(1R,5S,6S)-6-(aminometil)-3-etilbiciklo[3.2.0]hept-3-en-6-il]octena kiselina benzensulfonat; i
[(1S,5R,6R)-6-aminometil-3-etilbiciklo[3.2.0]hept-3-en-6-il]octena kiselina.
7. Farmaceutski pripravak koji kao djelatnu tvar sadrži spoj ili njegovu farmakološki prihvatljivu sol prema bilo kojem od zahtjeva 1 do 6.
8. Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji boli.
9. Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji bolesti izabrane iz grupe koja obuhvaća akutnu bol, kroničnu bol, bol uzrokovanu ozljedom mekog tkiva ili perifernom ozljedom, neuralgiju nakon herpesa, okcipitalnu neuralgiju, trigeminalnu neuralgiju, mijelomernu ili interkostanu neuralgiju, centralnu bol, neuropatsku bol, migrenu, bol povezanu s osteoartritisom ili artikularnom reumom, bol povezanu s udarcem, uganućem, ili traumom, spondilalgiju, bol uzrokovanu ozljedom leđne moždine ili moždanog debla, bol u donjem dijelu leđa, išijas, zubobolju, sindrom miofascijalne boli, bol od epiziotomije, bol od gihta, bol uzrokovanu opeklinom, srčanu bol, mišićnu bol, bol u očima, upalnu bol, orofacijalnu bol, abdominalnu bol, bol povezanu s dismenorejom, porođajnu bol, ili endometriozu, bol tijela, bol povezanu s ozljedom živaca ili radijalnom ozljedom, bol povezanu s amputacijom, tic douloureux, neurom, ili angiitis, bol uzrokovanu dijabetičkom neuropatijom (ili dijabetička periferna neuropatska bol), bol uzrokovanu kemoterapijom-induciranom neuropatijom, atipičnu facijalnu neuralgiju, neuropatsku bol u donjem dijelu leđa, neuralgiju povezanu s HIV-om, neuralgiju povezanu s AIDS-om, hiperalgeziju, goruću bol, iznenadnu bol, bol uzrokovanu kemoterapijom, okcipitalnu neuralgiju, psihogenu bol, bol povezanu sa žučnim kamencima, neuropatsku ili ne-neuropatsku bol povezanu s rakom, fantomsku bol udova, funkcionalnu abdominalnu bol, glavobolju, akutnu ili kroničnu tenzijsku glavobolju, sinusnu glavobolju, klaster glavobolju, temporomandibularnu bol zglobova, bol od maksilarnih sinusa, bol uzrokovanu ankilozantnim spondiloartritisom, postoperativnu bol, bol ožiljka, kroničnu ne-neuropatsku bol, fibromijalgiju, amiotropnu lateralnu sklerozu, epilepsiju (parcijalnu epilepsiju, adultni parcijalni napad, i parcijalni napad u bolesnika s epilepsijom), generalizirani anksiozni poremećaj i sindrom nemirnih nogu.
10. Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji boli koja je uzrokovana dijabetičkom neuropatijom.
11. Uporaba spoja ili njegove farmakološki prihvatljive soli prema bilo kojem od zahtjeva 1 do 6 za proizvodnju farmaceutskog pripravka za liječenje i/ili prevenciju boli.
12. Uporaba prema zahtjevu 11, gdje farmaceutski pripravak je pripravak za liječenje i/ili prevenciju boli koja je uzrokovana dijabetičkom neuropatijom.
13. Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji neuralgije nakon herpesa.
14. Uporaba spoja ili njegove farmakološki prihvatljive soli prema bilo kojem od zahtjeva 1 do 6 za proizvodnju farmaceutskog pripravka za liječenje i/ili prevenciju neuralgije nakon herpesa.
15. Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji fibromialgije.
16. Uporaba spoja ili njegove farmakološki prihvatljive soli prema bilo kojem od zahtjeva 1 do 6 za proizvodnju farmaceutskog pripravka za liječenje i/ili prevenciju fibromialgije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007255430 | 2007-09-28 | ||
| PCT/JP2008/067223 WO2009041453A1 (ja) | 2007-09-28 | 2008-09-25 | 二環性γ－アミノ酸誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130935T1 true HRP20130935T1 (hr) | 2013-11-22 |
Family
ID=40511336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130935AT HRP20130935T1 (hr) | 2007-09-28 | 2013-10-07 | Bicikliäśki derivat aminokiseline |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7947738B2 (hr) |
| EP (2) | EP2657219B1 (hr) |
| JP (1) | JP4479974B2 (hr) |
| KR (2) | KR101409079B1 (hr) |
| CN (2) | CN101878193B (hr) |
| AU (1) | AU2008304933B2 (hr) |
| BR (2) | BR122013020635A2 (hr) |
| CA (1) | CA2701110C (hr) |
| CO (1) | CO6270314A2 (hr) |
| CY (1) | CY1114836T1 (hr) |
| DK (1) | DK2192109T3 (hr) |
| ES (2) | ES2433890T3 (hr) |
| HK (2) | HK1139381A1 (hr) |
| HR (1) | HRP20130935T1 (hr) |
| IL (1) | IL204621A (hr) |
| MX (1) | MX2010003394A (hr) |
| MY (2) | MY172034A (hr) |
| NZ (1) | NZ584699A (hr) |
| PH (1) | PH12013501663B1 (hr) |
| PL (1) | PL2192109T3 (hr) |
| PT (1) | PT2192109E (hr) |
| RU (1) | RU2446148C2 (hr) |
| SI (1) | SI2192109T1 (hr) |
| TW (2) | TWI526425B (hr) |
| WO (1) | WO2009041453A1 (hr) |
| ZA (1) | ZA201002013B (hr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2192109E (pt) | 2007-09-28 | 2013-12-09 | Daiichi Sankyo Co Ltd | Derivado de -aminoácido bicíclico |
| WO2010079668A1 (ja) * | 2009-01-08 | 2010-07-15 | 第一三共株式会社 | オレフィン化合物 |
| KR101674700B1 (ko) * | 2009-03-26 | 2016-11-09 | 다이이찌 산쿄 가부시키가이샤 | 2고리성 γ-아미노산 유도체의 제조 방법 |
| EP2719677B1 (en) * | 2011-06-08 | 2017-09-06 | Daiichi Sankyo Company, Limited | Method for producing bicyclic compound via claisen rearrangement |
| ES2659162T3 (es) | 2011-06-08 | 2018-03-14 | Daiichi Sankyo Company, Limited | Procedimiento de producción de compuesto bicíclico a través de una sal de iminio |
| CA2859003C (en) | 2011-12-15 | 2016-11-01 | Daiichi Sankyo Company, Limited | Optical resolution method for bicyclic compound using asymmetric catalyst |
| WO2013089189A1 (ja) * | 2011-12-16 | 2013-06-20 | 第一三共株式会社 | ヒドロキシスルホン酸を経由する二環性化合物の光学分割方法 |
| KR101951379B1 (ko) * | 2012-02-08 | 2019-02-22 | 스텔라파머 가부시키가이샤 | 세레울라이드 및 그 유도체의 제조 방법, 세레울라이드 제조를 위한 중간체 및 세레울라이드 유도체 |
| CN104245951B (zh) * | 2012-04-10 | 2018-08-24 | 第一三共株式会社 | 使用酶对二环化合物光学拆分的方法 |
| JP5627062B1 (ja) * | 2013-04-04 | 2014-11-19 | 第一三共株式会社 | アミノカルボン酸の塩の固形組成物 |
| TWI635071B (zh) * | 2013-07-08 | 2018-09-11 | 第一三共股份有限公司 | 光學活性二環γ－胺基酸衍生物及其製造方法 |
| EP3083572B1 (en) * | 2013-12-18 | 2019-02-13 | Novassay SA | Gamma-aminobutyric acid (gaba) analogues for the treatment of pain and other disorders |
| EP3272346A4 (en) | 2015-03-19 | 2018-08-01 | Daiichi Sankyo Company, Limited | Solid preparation containing colorant |
| EP3272345B1 (en) | 2015-03-19 | 2019-10-16 | Daiichi Sankyo Company, Limited | Solid preparation containing antioxidant agent |
| WO2017107907A1 (zh) * | 2015-12-25 | 2017-06-29 | 四川海思科制药有限公司 | 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
| WO2017114225A1 (zh) * | 2015-12-31 | 2017-07-06 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
| CN106928080B (zh) * | 2015-12-31 | 2020-12-25 | 四川海思科制药有限公司 | 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
| WO2017183539A1 (ja) * | 2016-04-18 | 2017-10-26 | 第一三共株式会社 | メルドラム酸を用いる二環性化合物の製造方法 |
| TW201806928A (zh) * | 2016-07-01 | 2018-03-01 | 第一三共股份有限公司 | 胺基羧酸之酸加成鹽的結晶及其製造方法 |
| ES2906887T3 (es) * | 2016-07-21 | 2022-04-20 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivado del indol usado como inhibidor de CRTH2 |
| WO2018050046A1 (zh) | 2016-09-14 | 2018-03-22 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 |
| JP7051332B2 (ja) * | 2017-08-23 | 2022-04-11 | キヤノン株式会社 | 有機化合物及び光電変換素子 |
| JP7222063B2 (ja) * | 2018-07-12 | 2023-02-14 | 四川海思科制▲薬▼有限公司 | 縮合三環性γ－アミノ酸誘導体の組成物及びその調製 |
| WO2020011258A1 (zh) * | 2018-07-12 | 2020-01-16 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用 |
| ES2943883T3 (es) * | 2018-07-30 | 2023-06-16 | Daiichi Sankyo Co Ltd | Formulación de fármaco sólido que contiene estabilizador |
| WO2020029762A1 (zh) * | 2018-08-09 | 2020-02-13 | 四川海思科制药有限公司 | 稠合三环γ-氨基酸衍生物的制备方法及中间体 |
| CN114402198A (zh) * | 2019-09-03 | 2022-04-26 | 四川海思科制药有限公司 | 2-((1s,2s,3r,6s,8s)-2-(氨甲基)三环[4.2.1.03,8]壬烷-2-基)乙酸苯磺酸盐或其组合物杂质检测方法 |
| CN110511141B (zh) * | 2019-09-09 | 2022-04-29 | 上海凌凯医药科技有限公司 | 一种丙戊酰脲的合成方法 |
| EP4049679A4 (en) * | 2019-10-25 | 2023-11-01 | Kyoto University | PREVENTIVE OR THERAPEUTIC AGAINST TAUOPATHY |
| CN110818582B (zh) * | 2019-11-20 | 2023-06-09 | 合肥拓锐生物科技有限公司 | 一种gaba类似物及其盐，及其合成方法、应用、药物 |
| CN111116345A (zh) * | 2019-12-30 | 2020-05-08 | 上海华理生物医药股份有限公司 | 一种制备Mirogabalin的新方法 |
| EP4337327A1 (en) | 2021-05-12 | 2024-03-20 | Boehringer Ingelheim International GmbH | Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors |
| CN114195661B (zh) * | 2021-12-21 | 2023-12-22 | 苏州楚凯药业有限公司 | 一种苯磺酸米洛巴林的制备方法 |
| CN117986143A (zh) * | 2022-11-03 | 2024-05-07 | 中科中山药物创新研究院 | 含有多环结构的γ-氨基丁酸衍生物及其制备方法和用途 |
| CN116903468B (zh) * | 2023-07-14 | 2024-01-26 | 山东新时代药业有限公司 | 一种米洛巴林中间体的制备方法 |
| CN117800858B (zh) * | 2023-12-28 | 2024-06-21 | 南京津泓科技有限公司 | 一种米洛巴林催化氰基化制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19547766A1 (de) * | 1995-12-20 | 1997-06-26 | Gruenenthal Gmbh | 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe |
| SI1032555T1 (sl) | 1997-10-27 | 2006-08-31 | Warner Lambert Co | Ciklicne aminokisline in njihovi derivati, uporabni kot farmacevtska sredstva |
| HN2000000224A (es) | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| DE60235619D1 (de) | 2001-04-19 | 2010-04-22 | Warner Lambert Co | Kondensierte bizyklische oder trizyklische aminosäuren |
| GB2374595A (en) * | 2001-04-19 | 2002-10-23 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids |
| JP2005536507A (ja) | 2002-07-11 | 2005-12-02 | メルク エンド カムパニー インコーポレーテッド | ６Ｈ−ピロロ［３，４−ｄ］ピリダジン化合物による神経障害性疼痛の治療 |
| GB0223072D0 (en) * | 2002-10-04 | 2002-11-13 | Pfizer Ltd | Cyclic nitromethyl acetic acid derivatives |
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| PT2192109E (pt) | 2007-09-28 | 2013-12-09 | Daiichi Sankyo Co Ltd | Derivado de -aminoácido bicíclico |
-
2008
- 2008-09-25 PT PT88333992T patent/PT2192109E/pt unknown
- 2008-09-25 MX MX2010003394A patent/MX2010003394A/es active IP Right Grant
- 2008-09-25 KR KR1020137020763A patent/KR101409079B1/ko active IP Right Grant
- 2008-09-25 NZ NZ584699A patent/NZ584699A/en unknown
- 2008-09-25 MY MYPI2013003126A patent/MY172034A/en unknown
- 2008-09-25 ES ES08833399T patent/ES2433890T3/es active Active
- 2008-09-25 ES ES13177681T patent/ES2531324T3/es active Active
- 2008-09-25 BR BR122013020635-3A patent/BR122013020635A2/pt not_active Application Discontinuation
- 2008-09-25 CN CN200880118892.8A patent/CN101878193B/zh active Active
- 2008-09-25 JP JP2009534336A patent/JP4479974B2/ja active Active
- 2008-09-25 KR KR1020107006640A patent/KR101335784B1/ko active Protection Beyond IP Right Term
- 2008-09-25 DK DK08833399.2T patent/DK2192109T3/da active
- 2008-09-25 PL PL08833399T patent/PL2192109T3/pl unknown
- 2008-09-25 EP EP13177681.7A patent/EP2657219B1/en active Active
- 2008-09-25 MY MYPI2010001048A patent/MY153910A/en unknown
- 2008-09-25 CN CN201310389454.8A patent/CN103483169A/zh active Pending
- 2008-09-25 BR BRPI0818193A patent/BRPI0818193B8/pt active IP Right Grant
- 2008-09-25 EP EP08833399.2A patent/EP2192109B1/en active Active
- 2008-09-25 WO PCT/JP2008/067223 patent/WO2009041453A1/ja active Application Filing
- 2008-09-25 AU AU2008304933A patent/AU2008304933B2/en active Active
- 2008-09-25 CA CA2701110A patent/CA2701110C/en active Active
- 2008-09-25 SI SI200831100T patent/SI2192109T1/sl unknown
- 2008-09-25 RU RU2010116708/04A patent/RU2446148C2/ru active
- 2008-09-26 TW TW103112429A patent/TWI526425B/zh active
- 2008-09-26 TW TW097137036A patent/TWI436762B/zh active
-
2010
- 2010-02-26 US US12/714,267 patent/US7947738B2/en active Active
- 2010-03-19 ZA ZA2010/02013A patent/ZA201002013B/en unknown
- 2010-03-21 IL IL204621A patent/IL204621A/en active IP Right Grant
- 2010-04-28 CO CO10050291A patent/CO6270314A2/es active IP Right Grant
- 2010-06-21 HK HK10106099.5A patent/HK1139381A1/xx unknown
-
2013
- 2013-08-08 PH PH12013501663A patent/PH12013501663B1/en unknown
- 2013-10-07 HR HRP20130935AT patent/HRP20130935T1/hr unknown
- 2013-12-03 CY CY20131101078T patent/CY1114836T1/el unknown
-
2014
- 2014-04-22 HK HK14103804.4A patent/HK1190698A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130935T1 (hr) | Bicikliäśki derivat aminokiseline | |
| HRP20161713T1 (hr) | Derivat cikloalkana | |
| HRP20171829T1 (hr) | 2-piridil supstituirani imidazoli kao terapijski inhibitori alk5 i/ili alk4 | |
| MX2012001399A (es) | Profarmacos que comprenden un conjugado de insulina-conector. | |
| JP2013545730A5 (hr) | ||
| MY166866A (en) | Heterocyclic derivative and pharmaceutical drug | |
| RU2014131014A (ru) | Димерные соединения-агонисты рецептора fgf (fgfr), способ их получения и их терапевтическое применение | |
| MY158974A (en) | Prodrugs comprising an exendin linker conjugate | |
| WO2010124521A1 (zh) | 一种大黄酸衍生物及其制备和用途 | |
| BRPI0613077A2 (pt) | agonistas alfa-2 andrenérgicos para o tratamento de dor | |
| RU2009136592A (ru) | Терапевтические агенты | |
| JP2009526831A5 (hr) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| RU2011111117A (ru) | Лечение аутоиммунных заболеваний | |
| RU2014119711A (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| HRP20240173T1 (hr) | Fluorofenil beta-hidroksietilamini i njihova upotreba u liječenju hiperglikemije | |
| US11702406B1 (en) | Triazine derivatives and methods of use thereof | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. | |
| JP2014520810A5 (hr) | ||
| RU2014118330A (ru) | Соединения для лечения и профилактики заболевания, вызванного респираторным синцитиальным вирусом | |
| JP2012510985A5 (hr) | ||
| RU2010109369A (ru) | Замещенные 5-винилфенил-1-фенилпиразолы в качестве модуляторов каннабиноидов | |
| US9555021B2 (en) | Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| ES2665293T3 (es) | Compuesto para tratar estados con mediación alfa-adrenérgica | |
| JP2019529472A5 (hr) |